Microdosing Tirzepatide Chart: A Precise Conversion Reference for Sub-Clinical and Titration Doses

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• "Microdosing" tirzepatide usually means dosing below the labeled 2.5 mg starting dose, often in the 0.5 mg to 2.0 mg weekly range.
• The unit count for any microdose depends entirely on the vial concentration. At the most common 10 mg/mL concentration, 0.5 mg equals 5 units, 1 mg equals 10 units, 1.5 mg equals 15 units, and 2 mg equals 20 units.
• Microdosing is not an FDA-approved approach. It is a real-world strategy patients and prescribers use for slow titration, side-effect management, or maintenance dosing after weight loss goals are reached.
• Drawing tiny volumes accurately requires a 0.3 mL or 0.5 mL U-100 insulin syringe with half-unit markings. A 1 mL barrel makes microdoses harder to read.
• Microdoses are typically used short-term during titration or in the maintenance phase. They are not the same as the labeled clinical doses used in SURMOUNT trials.

Direct answer (40-60 words)

For compounded tirzepatide at the most common concentration of 10 mg/mL, microdoses convert to units as follows: 0.5 mg = 5 units, 1 mg = 10 units, 1.5 mg = 15 units, and 2 mg = 20 units on a U-100 insulin syringe. Lower doses than the labeled 2.5 mg starting dose are off-label and should be guided by a clinician.

Table of contents

1. The 30-second answer
2. What microdosing means in this context
3. Why patients ask about microdoses
4. Master microdosing conversion chart (every common concentration)
5. The 10 mg/mL chart explained
6. Lower-volume concentrations (5 mg/mL)
7. Higher-volume concentrations (15 and 20 mg/mL)
8. Reading a U-100 syringe at small volumes
9. When microdosing makes clinical sense
10. When microdosing does not make sense
11. Common microdosing schedules
12. FAQ
13. Sources

What microdosing means in this context

In the GLP-1 community, "microdosing" almost always means weekly tirzepatide doses below the labeled starting dose of 2.5 mg. The labeled tirzepatide titration ladder (per the Mounjaro and Zepbound prescribing information) is:

• Weeks 1 through 4: 2.5 mg weekly
• Weeks 5 through 8: 5 mg weekly
• Weeks 9 through 12: 7.5 mg weekly
• Weeks 13 onward: 10 mg, 12.5 mg, or 15 mg weekly per response

Microdoses fall below 2.5 mg. Common microdose targets include 0.5 mg, 1 mg, 1.5 mg, and 2 mg weekly. A few patients and clinicians also use the term to describe twice-weekly half doses (for example, 1.25 mg twice weekly to total 2.5 mg per week with smoother peaks), though that is more accurately called dose splitting.

Microdosing is not how the FDA approved tirzepatide. The SURMOUNT-1 registration trial (Jastreboff et al., NEJM 2022) tested 5, 10, and 15 mg weekly. There is no clinical trial data on chronic 0.5 mg or 1 mg weekly dosing. Patients and prescribers using these doses are working from pharmacokinetic extrapolation and clinical judgment, not trial data.

Why patients ask about microdoses

Three common reasons:

1. Slow titration to reduce side effects. Some patients tolerate a slower ramp than the labeled 4-week steps. Stepping up by 0.5 mg or 1 mg per week instead of jumping from 2.5 mg to 5 mg can reduce nausea and GI side effects in patients sensitive to dose changes.

2. Maintenance dosing. After reaching a weight goal, some patients work with their clinician to drop to a lower dose for maintenance rather than stopping the medication entirely. The 2.4 mg semaglutide STEP 4 data (Rubino et al., JAMA 2021) showed that stopping the drug fully causes most patients to regain weight; lower-dose maintenance is one strategy to avoid that without staying at full clinical dose.

3. Stretching supply. During periods of pen shortage or cost pressure, patients on compounded tirzepatide sometimes microdose to extend a vial. This is the least clinically defensible reason and is usually discouraged because subtherapeutic dosing wastes the active drug without producing the intended outcome.

Master microdosing conversion chart (every common concentration)

A few notes on this table:

• Doses below about 5 units on a U-100 syringe are hard to read accurately. A 0.3 mL syringe with half-unit markings helps, but precision below 2.5 units (0.025 mL) is poor.
• Above 40 mg/mL, most microdoses become so small (under 5 units) that drawing accuracy suffers. Most compounding pharmacies do not concentrate above 20 mg/mL for that reason.
• The 5 mg/mL concentration produces clean unit math and the easiest readability for low microdoses. The trade-off is a larger injection volume.

The 10 mg/mL chart explained

10 mg/mL is the workhorse concentration. The unit math is clean: every milligram corresponds to 10 units, so the unit count is simply the dose in mg multiplied by 10.

The 0.25 mg dose at 10 mg/mL pulls only 2.5 units, which is at the edge of what most insulin syringes can read accurately. Patients targeting that low a dose often switch to a 5 mg/mL concentration to get a larger, easier-to-read draw.

Lower-volume concentrations (5 mg/mL)

5 mg/mL doubles the volume per dose, which makes small microdoses easier to draw.

The trade-off: a 2.5 mg dose at 5 mg/mL is 50 units (half an entire 1 mL syringe), which is a larger injection volume and may sting slightly more. For patients escalating past microdose territory, switching back to 10 mg/mL at higher doses is common.

Higher-volume concentrations (15 and 20 mg/mL)

These concentrations are used to reduce vial size or fit more doses into a smaller bottle. The math gets uglier.

15 mg/mL chart:

20 mg/mL chart:

If your pharmacy dispenses 15 mg/mL or 20 mg/mL, microdosing becomes harder to do precisely without a 0.3 mL syringe with half-unit markings. Some patients ask for a 5 mg/mL or 10 mg/mL vial specifically for the cleaner math.

Reading a U-100 syringe at small volumes

The U-100 syringe markings differ by barrel size:

For microdoses, a 0.3 mL syringe with half-unit markings is the right tool. The smaller barrel spreads each unit across more visible distance, which makes 5 units vs 6 units a clear visual difference.

A 1 mL syringe used for a 5-unit draw squeezes that volume into a small fraction of the barrel, where each unit is barely 1 mm of plunger travel. The error margin for visual reading at that scale is high.

When microdosing makes clinical sense

Microdosing has clinical justification in three situations:

1. Patients who cannot tolerate the labeled titration. Some patients have severe nausea or vomiting on 2.5 mg. Stepping up from 1 mg to 1.5 mg to 2 mg over 6 to 8 weeks before reaching 2.5 mg can build tolerance gradually. The trade-off is a longer time to therapeutic dose.

2. Maintenance after weight goal. Patients who have reached their target weight may work with a clinician to drop to a low maintenance dose rather than stop entirely. Common maintenance microdoses are 1 mg to 2 mg weekly. Evidence for this approach is observational rather than trial-based.

3. Patients with a history of severe GLP-1 side effects who still need partial benefit. A small subset of patients get meaningful glycemic and appetite benefit at 1 mg or 1.5 mg weekly without the GI burden of higher doses. Whether this is sustained is unclear.

In all three cases, microdosing should be guided by a clinician who can assess response and adjust as needed.

When microdosing does not make sense

Stretching a vial to save money. A subtherapeutic dose still uses the drug. If the goal is weight loss, dosing below an effective level wastes vial volume without producing weight loss benefit. The math does not favor it.

Self-prescribed protocols without clinical input. Microdosing requires careful tracking of response and side effects. Working without a prescriber means no one is watching for pancreatitis, gallbladder issues, or thyroid signals.

As a starter dose without titration plan. Starting at 0.5 mg with no plan to increase is unlikely to produce meaningful weight loss. The SURMOUNT trials studied 5, 10, and 15 mg weekly. Doses below 2.5 mg have minimal published efficacy data for weight loss.

For patients with high BMI seeking rapid loss. Microdosing produces slower weight loss than labeled clinical dosing. Patients with BMI in the 35+ range are usually better served by following the standard titration ladder under medical supervision.

Common microdosing schedules

Three patterns appear most often in clinical practice:

Slow titration: 0.5 mg week 1, 1 mg week 2, 1.5 mg week 3, 2 mg week 4, 2.5 mg week 5. Stretches the labeled 2.5 mg starting block to allow gradual adaptation. Patients prone to nausea may add an extra week at each dose.

Maintenance microdosing: patient who hit goal weight at 7.5 mg drops to 5 mg, then 2.5 mg, then 1.5 mg over several months, monitoring weight. Stops the dose decrease at the lowest level that maintains weight stability.

Twice-weekly split: 1.25 mg twice weekly instead of 2.5 mg once weekly. Tirzepatide's half-life is about 5 days, so splitting into two injections produces lower peak concentrations and may reduce peak-related side effects. Total weekly dose is the same as a labeled 2.5 mg dose. Clinical evidence is anecdotal.

For any of these, a precise unit chart and a 0.3 mL syringe make execution accurate. (See our units to mg conversion guide for the standard dose chart.)

FAQ

What is microdosing tirzepatide? Microdosing tirzepatide means weekly doses below the labeled 2.5 mg starting dose, typically in the 0.5 mg to 2 mg range. It is used for slow titration, maintenance after weight loss, or to manage side effects. Microdosing is not FDA-approved and is not how tirzepatide was studied in clinical trials.

How many units is 0.5 mg of tirzepatide? At 10 mg/mL, 0.5 mg equals 5 units on a U-100 insulin syringe. At 5 mg/mL it is 10 units. At 15 mg/mL it is 3.3 units. At 20 mg/mL it is 2.5 units. Always confirm the concentration on your vial label before dosing.

How many units is 1 mg of tirzepatide? At 10 mg/mL, 1 mg equals 10 units. At 5 mg/mL it is 20 units. At 20 mg/mL it is 5 units. The unit count depends entirely on vial concentration.

What is the lowest dose of tirzepatide that works? The lowest dose with strong trial evidence for weight loss is 5 mg weekly (SURMOUNT-1). Doses below 2.5 mg have minimal published efficacy data. Some patients report subjective benefit at 1 to 2 mg, but the trial data does not support this as a primary weight loss strategy.

Can I microdose tirzepatide with a pen? Pens are designed for fixed labeled doses and are difficult to use for accurate microdoses. Some patients dial partial pen doses by counting clicks, but this introduces error. Most patients who microdose use compounded tirzepatide drawn from a vial with a U-100 syringe.

Why do some people microdose for maintenance? Stopping tirzepatide tends to produce weight regain. The SURMOUNT-4 trial showed that patients who switched from tirzepatide to placebo regained about 14 percentage points of body weight over 52 weeks (Aronne et al., JAMA 2024). Microdosing is one approach to maintain weight loss with less drug exposure than full clinical dosing, though long-term data is limited.

How often should I microdose tirzepatide? Weekly. Tirzepatide has a half-life of about 5 days, so steady-state concentrations are reached after weekly dosing for about 4 weeks. Some patients split the weekly dose into two half-doses to reduce side effect peaks, but the total weekly dose remains the same.

What syringe size is best for microdosing? A 0.3 mL U-100 insulin syringe with half-unit markings. The smaller barrel spreads small doses across more visible plunger travel, which improves dose accuracy at low volumes. A 1 mL syringe makes 5-unit and 10-unit doses harder to read precisely.

Is microdosing tirzepatide safe? The safety profile at low doses is similar to standard doses, with smaller magnitude. The same warnings apply: avoid in patients with personal or family history of medullary thyroid carcinoma, MEN 2, severe pancreatitis history, or known hypersensitivity. Microdosing should be supervised by a clinician.

Can I switch from clinical dosing to microdosing? Yes, with clinician guidance. Stepping down from 5 mg to 2.5 mg to 1.5 mg over several weeks lets the body adjust. Sudden drops can sometimes increase appetite rebound for a few weeks before stabilizing.

Does microdosing produce weight loss? Less than clinical dosing. SURMOUNT-1 showed average weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. Microdoses below 2.5 mg are extrapolated from pharmacokinetic data and clinical observation. Patients reporting weight loss on 1 to 2 mg weekly typically lose less and slower than at clinical doses.

How do I know my vial concentration? The concentration is printed on the vial label as "X mg/mL" or as a fraction like "100 mg/10 mL." If only total milligrams are listed, the concentration is in the pharmacy's dispensing instructions. Call the pharmacy if the concentration is unclear.

Sources

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331:38-48.
3. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
4. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
5. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. Updated 2024.
6. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company. Updated 2024.
7. U.S. Pharmacopeia General Chapter on Insulin Syringes (USP <3>). Most recent revision 2023.
8. Patel R, et al. Self-reported dosing errors with compounded GLP-1 receptor agonists. Ann Pharmacother. 2024.
9. FDA Drug Shortages Database. Tirzepatide entry resolved status, accessed 2026.
10. American Association of Clinical Endocrinology. Obesity Pharmacotherapy Algorithm. 2024.
11. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. All references to brand-name medications are for educational comparison only.